SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Walter Morton who wrote (1906)2/16/1999 11:29:00 AM
From: Steve Harmon  Read Replies (1) | Respond to of 2742
 
Looks like another deal is imminent. Will this one increase or enhance shareholder value?



To: Walter Morton who wrote (1906)2/19/1999 11:58:00 AM
From: Steve Harmon  Respond to of 2742
 
A lot of OTC BB stocks are gaining attention. See ALFN.

Cistron has 2 investment bankers, 1 Pr firm, and a highly paid CEO. Shareholder value has been increased $0 in 2 years since the $21 million IMNX settlement.

The CEO's contract expires on April 30.

CEO's are supposed to increase and protect shareholder value. Not "enhance" it.

Only 1 person has benefitted so far from the IMNX settlement--THE CEO...


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News